This presentation is under embargo until 14 July 2026, as per congress regulations
 

Please subscribe using the button below to receive a notification when the material becomes available:
 

Register for email alerts
 

Publication
  • ISTH •
  • 14 July, 2026 •
  • •

Joint Health Outcomes With Efanesoctocog Alfa Prophylaxis for Patients With Severe Hemophilia A: Third Interim Analysis of the Phase 3 XTEND-ed Study

Christoph Königs, Annette von Drygalski, Cedric Hermans, Barbara A. Konkle, María Teresa Álvarez Román, Liane Khoo, Nobuaki Suzuki, Graham Neill, Linda Bystrická, Meredith Foster, Elena Santagostino, Sriya Gunawardena, Robert Klamroth

Publication
  • ISTH •
  • 14 July, 2026 •
  • •

Baseline Characteristics of Patients Switching to Prophylactic Efanesoctocog Alfa Therapy Evaluated for Joint Health in Hemophilia A in Taiwan (PROTECT-ALT Study)

Yeu-Chin Chen, Ming-Ching Shen, Cheng-Wei Huang, Hung Chang, Jiaan-Der Wang, Sheng-Chieh Chou, Ching-Tien Peng, Chih-Cheng Hsiao, Chia-Yau Chang, Te-Fu Weng, Tong-Ling Chien, Ching-Min Chang, Shyh-Shin Chiou

Publication
  • ISTH •
  • 14 July, 2026 •
  • •

Interim analysis of the A-MORE real-world study: 4-year treatment outcomes with a recombinant factor VIII Fc in the overall and non-severe populations

Jan Astermark, Antonio Coppola, Swee Wenning, Ruben Berrueco, Ester Zapotocka, Andreu Schoenenberger López, Eva Bednar, Stefan Lethagen

Sign up for alerts